2026-11-17

AR1001 Achieved Primary Efficacy Objective in Phase 3 POLARIS-AD Trial in Alzheimer’s Disease, Slowing Clinical Decline in Prespecified Monotherapy Population

· The protocol of POLARIS-AD prespecified dual primary populations, each with a separate threshold for statistical significance. In the monotherapy population, AR1001 achieved statistical significance on primary endpoint, Clinical Dementia Rating Scale-Sum of Boxes(CDR-SB); the difference in the overall population numerically favored AR1001, but did not reach statistical significance.

· Cognitive and functional secondary measures numerically favored AR1001 across both populations, with a nominally significant Mini Mental State Examination(MMSE) finding in the monotherapy population.

· CSF biomarker findings support target engagement in the central nervous system.


SHANGHAI, China, November 17, 2026(November 16, 2026, U.S. Eastern Time) – Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; HKEX: 2196; SSE: 600196) today noted topline results from POLARIS-AD (NCT05531526), AriBio Co., Ltd.’s (“AriBio”) global Phase III registrational study of AR1001 in early Alzheimer’s disease, presented as the first oral presentation at the Clinical Trials on Alzheimer Disease conference (CTAD 2026) in Boston. AriBio reported that the study met its primary efficacy objective, demonstrating that AR1001 slows clinical decline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a measure of cognition and functions of daily life,at Week 52 in at least one of two prespecified primary populations.


AR1001 is a PDE5 inhibitor with an optimized fused-ring core structure,being studied for its potential to slow disease progression in early AD. AD remains one of the most challenging areas of drug development, and tens of millions of patients and families around the world have an urgent need for safe, effective and convenient treatment options.


POLARIS-AD is a global, randomized, double-blind, placebo-controlled Phase III clinical trial that enrolled 1,535 participants with early AD at approximately 230 clinical sites in 13 countries. Participants were randomized to AR1001 (30 mg) or placebo group, each taken orally once daily, over a 52-week double-blind treatment period in the main study. Eighty-eight percent of participants completed the 52-week double-blind treatment period, and more than 95% of eligible participants entered the open label long-term extension study.


The primary endpoint was evaluated in two prespecified primary populations, Overall and Monotherapy. The Monotherapy population comprised participants not receiving an acetylcholinesterase inhibitor or memantine at baseline.In the prespecified monotherapy population (n=604), AriBio reported that AR1001 slowed clinical decline by a statistically significant 31% versus placebo (treatment difference −0.44 points; p=0.0266, againsta pre-specified alpha threshold of 0.03), meeting the prespecified significance level for this population. In the overall population (n=1,535), the difference numerically favored AR1001 but did not reach statistical significance (−0.11 points,representing a 7% slowing of decline; p=0.4015, againsta pre-specified alpha threshold of 0.02).


Secondary cognitive and functional measures numerically favored AR1001 in both populations, with larger effects in the Monotherapy population. In the Monotherapy population, AR1001 showed a treatment difference of -1.16 points versus placebo on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 13 (ADAS-Cog 13; p=0.0798). AR1001 also showed a 0.7-point treatment difference versus placebo on the Mini-Mental State Examination (MMSE; nominal p=0.0232).


Consistent with AR1001’s mechanism of action, the analysis of cerebrospinal fluid (CSF) demonstrated increased cyclic guanosine monophosphate (cGMP) levels with AR1001 versus placebo at Week 52 in both the overall and monotherapy populations (nominal p<0.0001 overall; nominal p=0.0058 monotherapy). Additional biomarker support for 30mg AR1001 was seen with CSF p-tau217 results in both overall and monotherapy populations, with a -5.34 pg/mL difference favoring AR1001 in monotherapy (nominal p=0.0402). No difference in Aβ42/40 ratio was seen at Week 52.


AR1001 was generally well tolerated over the 52-week treatment phase. Treatment-emergent adverse events occurred in 69.0% of participants receiving AR1001 and 66.4% of those receiving placebo, and serious adverse events were similarly balanced (10.0% vs. 9.8%). Most adverse events were mild to moderate in severity. The most common non-serious adverse events with AR1001 were diarrhea (7.7% vs. 4.4% with placebo), falls (7.3% vs.5.9%) and dizziness (6.1% vs.3.1%).


Neurodegenerative disease is one of Fosun Pharma’s core therapeutic areas. Xingli Wang, President of Fosun Pharma, said: “AD remains one of the most serious challenges in medicine, and patients and their families urgently need more treatment options. POLARIS-AD has given us important Phase III data, including results in the prespecified monotherapy population, as well as safety data,fora once-daily oral therapy that could offer patients a convenient treatment option. We will remain patient-centered and, based on the complete body of evidence,continue to work closely with AriBio on the full dataset.”


###


About POLARIS-AD

POLARIS-AD (NCT05531526) is a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of AR1001 in participants with early Alzheimer’s disease. The study enrolled 1,535 participants across approximately 230 clinical sites in 13 countries. Participants were randomized to receive AR1001 30 mg or placebo once daily for 52 weeks. The primary endpoint is change from baseline to Week 52 in the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a measure of cognitive and functional impairment evaluated in two prespecified primary populations: overall and monotherapy. The primary efficacy objective required demonstration of slowing in at least one population under the prespecified multiplicity procedure. Additional assessments evaluate cognition, daily functioning and biomarkers associated with Alzheimer’s disease. A total of 1,349 (88%) participants completed the 52-week treatment period. More than 95% of eligible participants completing the main study opted to continue in the optional 52-week open-label extension study, in which all participants receive AR1001. 


About Fosun Pharma

Fosun Pharma (stock codes: 600196.SH; 02196.HK), founded in 1994, is an innovation-driven, global pharmaceutical and healthcare group with businesses spanning pharmaceuticals, medical devices and diagnostics, and healthcare services. With innovative drugs at the core of its growth, the company has built an open, global R&D system focused on major unmet clinical needs in oncology, immunology and inflammation, and neurodegenerative diseases, creating a product pipeline with long-term competitiveness. At the same time, it continues to strengthen core technology platforms including antibodies, ADCs, and small molecules, while actively expanding into frontier areas such as radiopharmaceuticals, small nucleic acids, peptides, and cell therapy, to accelerate the translation of research into real-world outcomes. Guided by its mission of “Better health for families worldwide” and its strategy of “Innovation-led, globally integrated, AI-enabled,” Fosun Pharma is committed to becoming a globally leading integrator of healthcare innovation.


For more information about the Group, please visit the company website: https://www.fosunpharma.com/en/


About AriBio

AriBio Co., Ltd. is a late clinical-stage biotechnology company headquartered in South Korea, with global clinical operations in San Diego, California, focused on developing therapies for neurodegenerative diseases and other areas of high unmet medical need. The company’s lead program, AR1001, is an investigational oral treatment candidate for Alzheimer’s disease. AR1005 is a Phase 2 oral candidate for the treatment of dementia with Lewy Bodies. AriBio is also advancing additional programs in dementia and related neurological disorders. 

 

Forward-looking statements

This press release contains forward-looking statements of Fosun Pharma. These forward-looking statements may include, but are not limited to: the potential therapeutic benefit and risk of AR1001, additional analyses and presentations of POLARIS-AD results, and planned regulatory communications. These statements reflect Fosun Pharma’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results or timelines to differ materially.


Such risks include, but are not limited to: additional analyses or safety findings that may change the interpretation of the reported results; uncertainty regarding whether the monotherapy findings will be confirmed in future studies or whether biomarker changes will translate into sustained clinical benefit; delays in completing the extension; and changes in development plans or resource availability. Regulatory authorities may interpret the results differently, require additional analyses or clinical trials, or delay or decline approval. The reported results do not guarantee regulatory approval.


AR1001 remains investigational for Alzheimer’s disease, and its safety and efficacy for this indication have not been established. Forward-looking statements speak only as of the date of this release. Readers should not place undue reliance on them. Except as required by applicable law, Fosun Pharma undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.